FDA Rejects Verily’s Smartwatch for Parkinson’s Assessment

FDA Rejects Verily’s Smartwatch for Parkinson’s Assessment

296443

FDA Rejects Verily’s Smartwatch for Parkinson’s Assessment

The U.S. Food and Drug Administration (FDA) has rejected an application from Verily Life Sciences that sought to add a Parkinson’s disease symptom assessment tool to the company’s clinical research-focused smartwatch. In its response letter, the FDA said there was not enough evidence that the criteria evaluated in the assessment were meaningful for patients’ lives. Verily’s smartwatch system — a wrist-worn device called Verily Study Watch — was designed to assess the motor abilities that are…

You must be logged in to read/download the full post.